The metropolis of Denver issued its first medical marijuana analysis and improvement license to review MJ-related therapies for ailments.
The license went to Denver-based medical marijuana firm MedPharm.
The allow permits the corporate to domesticate, course of, manufacture and switch marijuana to different laboratories or hashish companies for analysis functions.
Albert Gutierrez, CEO of MedPharm, instructed Marijuana Business Daily that a number of the previous analysis has relied on “subpar” hashish.
“Our focus is on providing high-quality dosage forms,” he stated.
MedPharm’s first undertaking can be to review marijuana’s impact on Alzheimer’s and dementia. The firm hopes to start out that undertaking by the tip of 2020.
MedPharm has its personal in-house laboratory to conduct research, and it’ll work with others similar to neurologists and laboratories that may, for instance, conduct mind scans.
In addition, the corporate is looking for partnerships.
The license resulted out of Colorado House Bill 17-1367, which took impact in 2018.
The Denver City Council accredited creating these licenses regionally on April 13.
“Our hope is that this new license type will lead to effective treatments for cancer, Alzheimer’s and other debilitating diseases so the full promise of legalized marijuana can be fulfilled,” Denver Excise and Licenses Executive Director Ashley Kilroy stated in a press release.
MedPharm was a part of the 14-company acquisition spree that Schwazze, previously often called Medicine Man Technologies, went on final 12 months.
– Bart Schaneman